Previous 10 | Next 10 |
Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (...
Report affirms Castle’s commitment to ESG principles and serves as a benchmark for future progress Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced t...
Study demonstrated improved prediction for sentinel lymph node (SLN) status compared to clinicopathologic features alone Study also demonstrated that DecisionDx®-Melanoma’s i31-GEP SLNB algorithm provides high correlation between prediction of SLN positivity rates ...
Castle Biosciences (NASDAQ:CSTL) announces an agreement with ModMed to establish an interface with ModMed’s electronic health records system, EMA. The interface is designed to enable dermatologic clinicians to order Castle’s DecisionDx skin cancer tests from directly within...
Interface facilitates ease of ordering within the dermatologic EMR platform Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced its agreement with ModMed to es...
i31-GEP for Risk of Recurrence algorithm integrates DecisionDx-Melanoma score with clinicopathologic factors to provide patient-specific five-year outcomes Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisio...
Presentation highlights data from second independent study validating DecisionDx® DiffDx ™ -Melanoma as an ancillary melanoma diagnostic tool for difficult-to-diagnose melanocytic lesions Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative ...
Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences Cernostics was originally supported by PLSG seed funding PR Newswire PITTSBURGH , Oct. 25, 2021 /PRNewswire/ -- Pittsburgh Life Scienc...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close ...
The Company also highlights the study design for its pipeline program to predict response to systemic therapeutics in patients diagnosed with moderate to severe inflammatory dermatologic conditions Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to t...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...